Generic Name: nivolumab-ipilimumab
Brand Name: Opdivo-Yervoy
Manufacturer: Bristol-Myers Squibb
Therapeutic Area: Malignant Pleural Mesothelioma (MPM)
Indications: OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
Manufacturer Requested Reimbursement Criteria1: OPDIVO, in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma.
Submission Type: Initial
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule1: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | September 30, 2020 |
| Call for patient/clinician input closed | November 19, 2020 |
| Clarification: - Patient input submission received from Lung Cancer Canada | |
| Submission received | October 29, 2020 |
| Submission accepted | November 12, 2020 |
| Review initiated | November 13, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | February 25, 2021 |
| Deadline for sponsors comments | March 08, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | April 05, 2021 |
| Expert committee meeting (initial) | April 15, 2021 |
| Draft recommendation issued to sponsor | April 27, 2021 To April 29, 2021 |